{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T22:21:43Z","timestamp":1791584503511,"version":"4.3.4"},"reference-count":170,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The phosphodiesterase (PDE) enzymes, key regulator of the cyclic nucleotide signal transduction system, are long-established as attractive therapeutic targets. During investigation of trends within clinical trials, we have identified a particularly high number of clinical trials involving PDE inhibitors, prompting us to further evaluate the current status of this class of therapeutic agents. In total, we have identified 87 agents with PDE-inhibiting capacity, of which 85 interact with PDE enzymes as primary target. We provide an overview of the clinical drug development with focus on the current clinical uses, novel molecules and indications, highlighting relevant clinical studies. We found that the bulk of current clinical uses for this class of therapeutic agents are chronic obstructive pulmonary disease (COPD), vascular and cardiovascular disorders and inflammatory skin conditions. In COPD, particularly, PDE inhibitors are characterised by the compliance-limiting adverse reactions. We discuss efforts directed to appropriately adjusting the dose regimens and conducting structure-activity relationship studies to determine the effect of structural features on safety profile. The ongoing development predominantly concentrates on central nervous system diseases, such as schizophrenia, Alzheimer\u2019s disease, Parkinson\u2019s disease and fragile X syndrome; notable advancements are being also made in mycobacterial infections, HIV and Duchenne muscular dystrophy. Our analysis predicts the diversification of PDE inhibitors\u2019 will continue to grow thanks to the molecules in preclinical development and the ongoing research involving drugs in clinical development.<\/jats:p>","DOI":"10.3389\/fphar.2022.1057083","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:37:58Z","timestamp":1669297078000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["Recent developments of phosphodiesterase inhibitors: Clinical trials, emerging indications and novel molecules"],"prefix":"10.3389","volume":"13","author":[{"given":"Andrey D.","family":"Bondarev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misty M.","family":"Attwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u0308rgen","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir N.","family":"Chubarev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim V.","family":"Tarasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi B.","family":"Schio\u0308th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"B1","unstructured":"AdisInsight database (2022)2022"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/b978-0-12-013312-3.50004-2","article-title":"Cyclic nucleotides as targets for drug design","volume":"12","author":"Amer","year":"1977","journal-title":"Adv. Drug Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors - pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/npr2.12108","article-title":"Combination of the phosphodiesterase 10A inhibitor, MR1916 with risperidone shows additive antipsychotic-like effects without affecting cognitive enhancement and cataleptic effects in rats","volume":"40","author":"Arakawa","year":"2020","journal-title":"Neuropsychopharmacol. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuro.2016.11.012","article-title":"Caffeine for apnea of prematurity: Effects on the developing brain","volume":"58","author":"Atik","year":"2017","journal-title":"Neurotoxicology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: Targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"B7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.tips.2018.03.003","article-title":"Orphan drugs and their impact on pharmaceutical development","volume":"39","author":"Attwood","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"B8","article-title":"Milrinone","volume-title":"StatPearls","author":"Ayres","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1038\/s41573-019-0033-4","article-title":"Therapeutic targeting of 3', 5'-cyclic nucleotide phosphodiesterases: Inhibition and beyond","volume":"18","author":"Baillie","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B10","doi-asserted-by":"publisher","first-page":"CD012621","DOI":"10.1002\/14651858.CD012621.pub2","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","volume":"1","author":"Barnes","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B11","first-page":"597","article-title":"Effects of xanthine derivatives on lipolysis and on adenosine 3', 5'-monophosphate phosphodiesterase activity","volume":"6","author":"Beavo","year":"1970","journal-title":"Mol. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2165\/00044011-200525090-00001","article-title":"Amlexanox for the treatment of recurrent aphthous ulcers","volume":"25","author":"Bell","year":"2005","journal-title":"Clin. Drug Investig."},{"key":"B13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: Molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"B174","doi-asserted-by":"publisher","first-page":"e109862","DOI":"10.1371\/journal.pone.0109862","article-title":"PDE2 is a novel target for attenuating tumor formation in a mouse model of UVB-induced skin carcinogenesis","volume":"9","author":"Bernard","year":"2014","journal-title":"PLoS One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","article-title":"Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: A randomized, placebo-controlled, phase 2 clinical trial","volume":"27","author":"Berry-Kravis","year":"2021","journal-title":"Nat. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11899-016-0335-0","article-title":"The use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia","volume":"11","author":"Birgeg\u00e5rd","year":"2016","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"101814","DOI":"10.1016\/j.pupt.2019.101814","article-title":"Efficacy and safety of a first-in-class inhaled PDE3\/4 inhibitor (ensifentrine) vs salbutamol in asthma","volume":"58","author":"Bjermer","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"ofz246","DOI":"10.1093\/ofid\/ofz246","article-title":"A phase I, randomized, controlled clinical study of CC-11050 in people living with HIV with suppressed plasma viremia on antiretroviral therapy (APHRODITE)","volume":"6","author":"Boulougoura","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"10518","DOI":"10.1073\/pnas.1834280100","article-title":"A mouse model of rubinstein-taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4","volume":"100","author":"Bourtchouladze","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B20","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1093\/schbul\/sby049","article-title":"Evaluation of the efficacy, safety, and tolerability of BI 409306, a novel phosphodiesterase 9 inhibitor, in cognitive impairment in schizophrenia: A randomized, double-blind, placebo-controlled, phase II trial","volume":"45","author":"Brown","year":"2019","journal-title":"Schizophr. Bull."},{"key":"B21","doi-asserted-by":"publisher","first-page":"CD003748","DOI":"10.1002\/14651858.CD003748.pub5","article-title":"Cilostazol for intermittent claudication","volume":"6","author":"Brown","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1310\/hpj4908-752","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm."},{"key":"B24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1164\/rccm.200610-1563OC","article-title":"Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease","volume":"176","author":"Calverley","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3389\/fonc.2017.00042","article-title":"Cytotoxicity of zardaverine in embryonal rhabdomyosarcoma from a costello syndrome patient","volume":"7","author":"Cartledge","year":"2017","journal-title":"Front. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"H2272","DOI":"10.1152\/ajpheart.00654.2010","article-title":"Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA\/Rho-kinase pathway","volume":"300","author":"Chau","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.eururo.2015.03.031","article-title":"Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: A trade-off network meta-analysis","volume":"68","author":"Chen","year":"2015","journal-title":"Eur. Urol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/17460441.2020.1821643","article-title":"An update of cyclic nucleotide phosphodiesterase as a target for cardiac diseases","volume":"16","author":"Chen","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1021\/acschemneuro.0c00106","article-title":"PDE-7 inhibitor BRL-50481 reduces neurodegeneration and long-term memory deficits in mice following sevoflurane exposure","volume":"11","author":"Chen","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"B30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/0024-3205(88)90517-6","article-title":"Caffeine and theophylline analogues: Correlation of behavioral effects with activity as adenosine receptor antagonists and as phosphodiesterase inhibitors","volume":"43","author":"Choi","year":"1988","journal-title":"Life Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/CRD.0000000000000165","article-title":"Milrinone dosing and a culture of caution in clinical practice","volume":"26","author":"Chong","year":"2018","journal-title":"Cardiol. Rev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","article-title":"Biochemistry and physiology of cyclic nucleotide phosphodiesterases: Essential components in cyclic nucleotide signaling","volume":"76","author":"Conti","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0304-4165(80)90063-x","article-title":"Characteristics of a new binding protein distinct from the kinase for guanosine 3':5'-monophosphate in rat platelets","volume":"631","author":"Coquil","year":"1980","journal-title":"Biochim. Biophys. Acta"},{"key":"B35","doi-asserted-by":"publisher","first-page":"5848","DOI":"10.1002\/cncr.27540","article-title":"Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: Evaluation of potential chemopreventive activity","volume":"118","author":"Curiel-Lewandrowski","year":"2012","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1073\/pnas.86.10.3604","article-title":"Cloning and characterization of mammalian homologs of the Drosophila dunce+ gene","volume":"86","author":"Davis","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B37","doi-asserted-by":"crossref","first-page":"P2.8","DOI":"10.1212\/WNL.92.15_supplement.P2.8-051","article-title":"ITI-214, A novel phosphodiesterase I inhibitor for the treatment of Parkinson\u2019s disease: Results from A phase I\/II clinical study (P2.8-051)","volume":"92","author":"Davis","year":"2019","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/21623945.2021.1965315","article-title":"Resveratrol supplementation reduces ACE2 expression in human adipose tissue","volume":"10","author":"de Ligt","year":"2021","journal-title":"Adipocyte"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1161\/01.CIR.0000165128.39715.87","article-title":"Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: Implication in heart failure","volume":"111","author":"Ding","year":"2005","journal-title":"Circulation"},{"key":"B40","first-page":"513","article-title":"CC-1088 celgene","volume":"6","author":"Dredge","year":"2005","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"B41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-319-69535-8_5","article-title":"Phosphodiesterase inhibitors (PDE inhibitors) and male reproduction","volume":"1034","author":"Drobnis","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543784.11.1.1","article-title":"Update on the therapeutic potential of PDE4 inhibitors","volume":"11","author":"Dyke","year":"2002","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: A phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1067\/mai.2001.119555","article-title":"Cyclic nucleotide phosphodiesterases","volume":"108","author":"Essayan","year":"2001","journal-title":"J. Allergy Clin. Immunol."},{"key":"B45","unstructured":"EMA Medicines database"},{"key":"B46","unstructured":"E.U. Clinical trials register"},{"key":"B47","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2165\/00126839-200405040-00007","article-title":"Exisulind: Aptosyn, FGN 1, prevatac, sulindac sulfone","volume":"5","year":"2004","journal-title":"Drugs R. D."},{"key":"B48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejphar.2005.12.059","article-title":"Phosphodiesterase inhibitors in airways disease","volume":"533","author":"Fan Chung","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1152\/physrev.00030.2010","article-title":"Mammalian cyclic nucleotide phosphodiesterases: Molecular mechanisms and physiological functions","volume":"91","author":"Francis","year":"","journal-title":"Physiol. Rev."},{"key":"B50","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/s0021-9258(19)86221-x","article-title":"Characterization of a novel cGMP binding protein from rat lung","volume":"255","author":"Francis","year":"1980","journal-title":"J. Biol. Chem."},{"key":"B51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-642-13443-2_4","article-title":"Inhibition of cyclic nucleotide phosphodiesterases by methylxanthines and related compounds","volume":"200","author":"Francis","year":"","journal-title":"Handb. Exp. Pharmacol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-019-0467-2","article-title":"Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease","volume":"11","author":"Fr\u00f6lich","year":"2019","journal-title":"Alzheimers Res. Ther."},{"key":"B53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1006\/bbrc.2000.2743","article-title":"Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase","volume":"272","author":"Gardner","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B54","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1080\/14737175.2017.1268531","article-title":"Phosphodiesterase 10 inhibitors in clinical development for CNS disorders","volume":"17","author":"Geerts","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e008236","DOI":"10.1161\/CIRCHEARTFAILURE.120.008236","article-title":"Acute hemodynamic effects and tolerability of phosphodiesterase-1 inhibition with ITI-214 in human systolic heart failure","volume":"14","author":"Gilotra","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"B56","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.3390\/ijms21155338","article-title":"Phosphodiesterase inhibitors: Could they Be beneficial for the treatment of COVID-19?","volume":"21","author":"Giorgi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B57","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/JTO.0b013e3181951eb0","article-title":"A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: Calgb 30104","volume":"4","author":"Govindan","year":"2009","journal-title":"J. Thorac. Oncol."},{"key":"B171","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1046\/j.1365-2249.2000.01332.x","article-title":"Thalidomide analogue CC-3052 reduces HIV+ neutrophil apoptosis in vitro","volume":"121","author":"Guckian","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fnmol.2019.00022","article-title":"Genetic association of phosphodiesterases with human cognitive performance","volume":"12","author":"Gurney","year":"2019","journal-title":"Front. Mol. Neurosci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"4884","DOI":"10.1021\/acs.jmedchem.9b00193","article-title":"Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of fragile X syndrome and other brain disorders","volume":"62","author":"Gurney","year":"2019","journal-title":"J. Med. Chem."},{"key":"B60","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.drudis.2007.07.023","article-title":"PDE inhibitors in psychiatry--future options for dementia, depression and schizophrenia?","volume":"12","author":"Halene","year":"2007","journal-title":"Drug Discov. Today"},{"key":"B172","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1016\/j.bmc.2015.04.052","article-title":"Addressing phototoxicity observed in a novel series of biaryl derivatives: Discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436","volume":"23","author":"Hamaguchi","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"16152","DOI":"10.1074\/jbc.272.26.16152","article-title":"Alternative splicing of the high affinity cAMP-specific phosphodiesterase (PDE7A) mRNA in human skeletal muscle and heart","volume":"272","author":"Han","year":"1997","journal-title":"J. Biol. Chem."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.cellsig.2014.03.031","article-title":"Role of phosphodiesterase 2 in growth and invasion of human malignant melanoma cells","volume":"26","author":"Hiramoto","year":"2014","journal-title":"Cell. Signal."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.3390\/ijerph18052483","article-title":"A placebo-controlled, pseudo- randomized, crossover trial of botanical agents for Gulf war illness: Resveratrol (polygonum cuspidatum), luteolin, and fisetin (rhus succedanea)","volume":"18","author":"Hodgin","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B64","doi-asserted-by":"publisher","first-page":"CD002309","DOI":"10.1002\/14651858.CD002309.pub6","article-title":"Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease","volume":"5","author":"Janjua","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B65","doi-asserted-by":"publisher","first-page":"CD011919","DOI":"10.1002\/14651858.CD011919.pub2","article-title":"Resveratrol for adults with type 2 diabetes mellitus","volume":"1","author":"Jeyaraman","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"B176","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.pbb.2015.04.017","article-title":"Pharmacological evaluation of a novel phosphodiesterase 10A inhibitor in models of antipsychotic activity and cognition","volume":"135","author":"Jones","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B66","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3389\/fphar.2020.00609","article-title":"Respiratory cilia as a therapeutic target of phosphodiesterase inhibitors","volume":"11","author":"Joskova","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"518345","DOI":"10.3389\/fphar.2021.518345","article-title":"Phosphodiesterase-4 inhibitors for non-COPD respiratory diseases","volume":"12","author":"Kawamatawong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3109\/02770909209048938","article-title":"Effect of ibudilast: A novel antiasthmatic agent, on airway hypersensitivity in bronchial asthma","volume":"29","author":"Kawasaki","year":"1992","journal-title":"J. Asthma"},{"key":"B70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12272-021-01367-x","article-title":"The effects of BRL-50481 on ovalbumin-induced asthmatic lung inflammation exacerbated by co-exposure to Asian sand dust in the murine model","volume":"45","author":"Kim","year":"2022","journal-title":"Arch. Pharm. Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: New data content and improved web interfaces","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1365-2222.1993.tb03240.x","article-title":"The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin-induced airway changes in rats","volume":"23","author":"Kips","year":"1993","journal-title":"Clin. Exp. Allergy"},{"key":"B73","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40035-022-00296-z","article-title":"Advances in the development of new biomarkers for Alzheimer's disease","volume":"11","author":"Klyucherev","year":"2022","journal-title":"Transl. Neurodegener."},{"key":"B74","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/ijms18040696","article-title":"Phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair","volume":"18","author":"Knott","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1177\/002215540004800512","article-title":"Immunohistochemical localization of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in rat tissues","volume":"48","author":"Kotera","year":"2000","journal-title":"J. Histochem. Cytochem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1017\/S109285291900124X","article-title":"Keeping up with the therapeutic advances in schizophrenia: A review of novel and emerging pharmacological entities","volume":"24","author":"Krogmann","year":"2019","journal-title":"CNS Spectr."},{"key":"B77","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000513377","article-title":"Treatment of essential thrombocythemia with anagrelide is associated with an increased risk of worsened kidney function","volume":"106","author":"Kwiatkowski","year":"2021","journal-title":"Pharmacology"},{"key":"B173","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1046\/j.1365-2249.2000.01117.x","article-title":"The thalidomide analogue CC-3052 inhibits HIV-1 and tumour necrosis factor-alpha (TNF-alpha) expression in acutely and chronically infected cells in vitro","volume":"119","author":"La Maestra","year":"2000","journal-title":"Clin. Exp. Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"e15500","DOI":"10.1111\/dth.15500","article-title":"Recurrent aphthous stomatitis: A comprehensive review and recommendations on therapeutic options","volume":"35","author":"Lau","year":"2022","journal-title":"Dermatol. Ther."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/1545968307305521","article-title":"A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia","volume":"21","author":"MacDonald","year":"2007","journal-title":"Neurorehabil. Neural Repair"},{"key":"B81","unstructured":"Global PDE inhibitors market size, share, trends, COVID-19 impact and growth analysis report \u2013 segmented by application2022"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1517\/13543784.2014.921157","article-title":"PDE inhibitors currently in early clinical trials for the treatment of asthma","volume":"23","author":"Matera","year":"2014","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B83","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"B84","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/ejh.13454","article-title":"Anagrelide in essential thrombocythemia (ET): Results from 150 patients over 25 years by the \"Ph1-negative myeloproliferative neoplasms latium group","volume":"105","author":"Mazzucconi","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1124\/jpet.113.211904","article-title":"Pharmacology of JNJ-42314415, a centrally active phosphodiesterase 10A (PDE10A) inhibitor: A comparison of PDE10A inhibitors with D2 receptor blockers as potential antipsychotic drugs","volume":"349","author":"Megens","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B86","doi-asserted-by":"publisher","first-page":"600178","DOI":"10.3389\/fnins.2020.600178","article-title":"PDE10A inhibitors-clinical failure or window into antipsychotic drug action?","volume":"14","author":"Menniti","year":"2021","journal-title":"Front. Neurosci."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1002\/ppul.24082","article-title":"Phosphodiesterase inhibitors: Potential role in the respiratory distress of neonates","volume":"53","author":"Mokra","year":"2018","journal-title":"Pediatr. Pulmonol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.3390\/ijms22041929","article-title":"Phosphodiesterase inhibitors in acute lung injury: What are the perspectives?","volume":"22","author":"Mokra","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.resp.2018.01.008","article-title":"Inhibitors of phosphodiesterases in the treatment of cough","volume":"257","author":"Mokry","year":"2018","journal-title":"Respir. Physiol. Neurobiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1046\/j.1365-2141.2003.04777.x","article-title":"The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures","volume":"124","author":"Molostvov","year":"2004","journal-title":"Br. J. Haematol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-016-0779-0","article-title":"Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease","volume":"14","author":"Moussa","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"B92","doi-asserted-by":"publisher","first-page":"6057","DOI":"10.21873\/anticanres.13812","article-title":"Role of Phosphodiesterase2A in proliferation and migration of human osteosarcoma cells","volume":"39","author":"Murata","year":"2019","journal-title":"Anticancer Res."},{"key":"B93","doi-asserted-by":"publisher","first-page":"e2036337","DOI":"10.1001\/jamanetworkopen.2020.36337","article-title":"Assessment of combination therapies vs monotherapy for erectile dysfunction: A systematic review and meta-analysis","volume":"4","author":"Mykoniatis","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B94","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jacc.2008.08.069","article-title":"Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload","volume":"53","author":"Nagayama","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"a005926","DOI":"10.1101\/cshperspect.a005926","article-title":"Second messengers","volume":"8","author":"Newton","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"797390","DOI":"10.3389\/fimmu.2021.797390","article-title":"The PDE4 inhibitor tanimilast blunts proinflammatory dendritic cell activation by SARS-CoV-2 ssRNAs","volume":"12","author":"Nguyen","year":"2022","journal-title":"Front. Immunol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1124\/mol.57.4.738","article-title":"Differential inhibition of multiple cAMP phosphodiesterase isozymes by isoflavones and tyrphostins","volume":"57","author":"Nichols","year":"2000","journal-title":"Mol. Pharmacol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1096\/fj.201700249R","article-title":"Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy","volume":"31","author":"Nio","year":"2017","journal-title":"FASEB J."},{"key":"B99","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1007\/s12035-016-0355-8","article-title":"Can cyclic nucleotide phosphodiesterase inhibitors Be drugs for Parkinson's disease?","volume":"55","author":"Nthenge-Ngumbau","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/13543784.2019.1571582","article-title":"Experimental and investigational phosphodiesterase inhibitors in development for asthma","volume":"28","author":"Ntontsi","year":"2019","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B101","doi-asserted-by":"publisher","first-page":"103449","DOI":"10.1016\/j.mcn.2019.103449","article-title":"Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses","volume":"102","author":"O'Brien","year":"2020","journal-title":"Mol. Cell. Neurosci."},{"key":"B102","doi-asserted-by":"publisher","first-page":"H1263","DOI":"10.1152\/ajpheart.00324.2002","article-title":"Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits","volume":"283","author":"Ockaili","year":"2002","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/978-3-642-17969-3_17","article-title":"Phosphodiesterase inhibitors in the treatment of inflammatory diseases","volume":"2011","author":"Page","year":"2011","journal-title":"Handb. Exp. Pharmacol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"777494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"B105","unstructured":"PaloBioPharma pipeline2022"},{"key":"B106","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/ddr.430120203","article-title":"Cyclic AMP and cyclic GMP phosphodiesterases: Target for drug development","volume":"12","author":"Pang","year":"1988","journal-title":"Drug Dev. Res."},{"key":"B107","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/S0140-6736(17)33311-1","article-title":"Asthma","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1093\/bioinformatics\/bty633","article-title":"Ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R","volume":"35","author":"Paradis","year":"2019","journal-title":"Bioinformatics"},{"key":"B109","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.cell.2012.01.017","article-title":"Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases","volume":"148","author":"Park","year":"2012","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1124\/jpet.116.237271","article-title":"Potential L-type voltage-operated calcium channel blocking effect of drotaverine on functional models","volume":"359","author":"Patai","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1111\/bph.14350","article-title":"Targeting the dopamine D1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance","volume":"175","author":"Pekcec","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.ejmech.2018.03.046","article-title":"Inhibitors of phosphodiesterase as cancer therapeutics","volume":"150","author":"Peng","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"B113","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1038\/npp.2014.154","article-title":"The PDE4 inhibitor HT- 0712 improves hippocampus-dependent memory in aged mice","volume":"39","author":"Peters","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"B114","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(17)31222-9","article-title":"Chronic obstructive pulmonary disease","volume":"389","author":"Rabe","year":"2017","journal-title":"Lancet"},{"key":"B115","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4103\/1319-3767.145331","article-title":"Efficacy and safety of drotaverine hydrochloride in irritable bowel syndrome: A randomized double-blind placebo-controlled study","volume":"20","author":"Rai","year":"2014","journal-title":"Saudi J. Gastroenterol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd3478","article-title":"Trends in the exploitation of novel drug targets","volume":"10","author":"Rask-Andersen","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"B117","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1146\/annurev-pharmtox-011613-135943","article-title":"The druggable genome: Evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication","volume":"54","author":"Rask-Andersen","year":"2014","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/01.crd.0000233904.77128.49","article-title":"Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease","volume":"15","author":"Ravipati","year":"2007","journal-title":"Cardiol. Rev."},{"key":"B119","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ejphar.2015.04.040","article-title":"Characterisation of Lu AF33241: A novel, brain-penetrant, dual inhibitor of phosphodiesterase (PDE) 2A and PDE10A","volume":"761","author":"Redrobe","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1042\/BJ20050030","article-title":"Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue","volume":"388","author":"Richter","year":"2005","journal-title":"Biochem. J."},{"key":"B121","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00395-010-0138-8","article-title":"Conserved expression and functions of PDE4 in rodent and human heart","volume":"106","author":"Richter","year":"2011","journal-title":"Basic Res. Cardiol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1530\/JOE-14-0335","article-title":"Resveratrol and curcumin enhance pancreatic \u03b2-cell function by inhibiting phosphodiesterase activity","volume":"223","author":"Rouse","year":"2014","journal-title":"J. Endocrinol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00702-010-0507-3","article-title":"The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis","volume":"117","author":"Rundfeldt","year":"2010","journal-title":"J. Neural Transm."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1007\/s13555-022-00751-9","article-title":"Difamilast ointment in Japanese adult and pediatric patients with atopic dermatitis: A phase III, long-term, open-label study","volume":"12","author":"Saeki","year":"2022","journal-title":"Dermatol. Ther."},{"key":"B125","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1210\/endo.140.5.6686","article-title":"Type 4 cyclic adenosine monophosphate-specific phosphodiesterases are expressed in discrete subcellular compartments during rat spermiogenesis","volume":"140","author":"Salanova","year":"1999","journal-title":"Endocrinology"},{"key":"B126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/biomedicines6030091","article-title":"Resveratrol: A double-edged sword in Health benefits","volume":"6","author":"Salehi","year":"2018","journal-title":"Biomedicines"},{"key":"B127","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1006\/bbrc.2000.2661","article-title":"Identification of human PDE7B, a cAMP-specific phosphodiesterase","volume":"271","author":"Sasaki","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B128","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","article-title":"Phosphodiesterase 4 in inflammatory diseases: Effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex","volume":"28","author":"Schafer","year":"2016","journal-title":"Cell. Signal."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa054065","article-title":"Caffeine therapy for apnea of prematurity","volume":"354","author":"Schmidt","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B130","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa073679","article-title":"Long-term effects of caffeine therapy for apnea of prematurity","volume":"357","author":"Schmidt","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B175","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/0006-291x(89)91724-5","article-title":"Evaluation of the effects of erythro-9(2-hydroxy-3-nonyl) adenine (EHNA) on HIV-1 production in vitro","volume":"164","author":"Sei","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B131","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s0079-6603(00)66031-2","article-title":"Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family","volume":"66","author":"Shakur","year":"2001","journal-title":"Prog. Nucleic Acid. Res. Mol. Biol."},{"key":"B132","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0020-7292(03)00276-5","article-title":"Drotaverine hydrochloride for augmentation of labor","volume":"84","author":"Singh","year":"2004","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"B133","doi-asserted-by":"publisher","first-page":"L279","DOI":"10.1152\/ajplung.00170.2002","article-title":"Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells","volume":"284","author":"Smith","year":"2003","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s00213-016-4346-2","article-title":"Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats","volume":"233","author":"Snyder","year":"2016","journal-title":"Psychopharmacol. Berl."},{"key":"B135","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/978-3-319-58811-7_14","article-title":"PDE inhibitors for the treatment of schizophrenia","volume":"17","author":"Snyder","year":"2017","journal-title":"Adv. Neurobiol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pharmrev.121.000317","article-title":"Brain cancer drug discovery: Clinical trials, drug classes, targets, and combinatorial therapies","volume":"73","author":"Sokolov","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"B137","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/164_2016_71","article-title":"Xanthines and phosphodiesterase inhibitors","volume":"237","author":"Spina","year":"2017","journal-title":"Handb. Exp. Pharmacol."},{"key":"B138","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3389\/fimmu.2016.00238","article-title":"Pharmacologic inhibition of host phosphodiesterase-4 improves isoniazid-mediated clearance of Mycobacterium tuberculosis","volume":"7","author":"Subbian","year":"2016","journal-title":"Front. Immunol."},{"key":"B139","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ebiom.2016.01.015","article-title":"Adjunctive phosphodiesterase-4 inhibitor therapy improves antibiotic response to pulmonary tuberculosis in a rabbit model","volume":"4","author":"Subbian","year":"2016","journal-title":"EBioMedicine"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/j.cellsig.2007.03.012","article-title":"Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice","volume":"19","author":"Sun","year":"2007","journal-title":"Cell. Signal."},{"key":"B141","doi-asserted-by":"publisher","first-page":"e90627","DOI":"10.1371\/journal.pone.0090627","article-title":"Phosphodiesterase 3\/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition","volume":"9","author":"Sun","year":"2014","journal-title":"PLoS One"},{"key":"B142","first-page":"91","article-title":"Excerpts from the clinical-pharmacologic and clinical studies of Grandaxin","volume":"63","author":"Szeg\u00f3","year":"1993","journal-title":"Acta Pharm. hung."},{"key":"B143","unstructured":"Global phosphodiesterase (PDE) inhibitors market 2022-20262022"},{"key":"B144","unstructured":"Tetra discovery partners announces positive results from phase 1 studies of cognition drug candidateBPN147702016"},{"key":"B145","unstructured":"The national Institute of Health2022"},{"key":"B147","unstructured":"Drugs@FDA: FDA approved drug products2018"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1042\/BST20190763","article-title":"Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches","volume":"47","author":"Tibbo","year":"2019","journal-title":"Biochem. Soc. Trans."},{"key":"B149","doi-asserted-by":"publisher","first-page":"a021196","DOI":"10.1101\/cshperspect.a021196","article-title":"Host-directed therapies for tuberculosis","volume":"5","author":"Tobin","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B150","doi-asserted-by":"publisher","first-page":"e1735","DOI":"10.1542\/peds.2014-2812","article-title":"Atopic dermatitis: Skin-directed management","volume":"134","author":"Tollefson","year":"2014","journal-title":"Pediatrics"},{"key":"B151","unstructured":"PDE inhibitors market - global industry analysis, size, share, growth, trends, and forecast202120312021"},{"key":"B152","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.coph.2011.09.003","article-title":"The roles of cyclic nucleotide phosphodiesterases (PDEs) in steroidogenesis","volume":"11","author":"Tsai","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"B153","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"B154","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1111\/bph.14920","article-title":"Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease","volume":"177","author":"Tzoumas","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"B155","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","article-title":"UniProt: The universal protein knowledgebase in 2021","volume":"49","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"B156","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1095\/biolreprod.104.039180","article-title":"Identification of a new variant of PDE1A calmodulin-stimulated cyclic nucleotide phosphodiesterase expressed in mouse sperm","volume":"73","author":"Vasta","year":"2005","journal-title":"Biol. Reprod."},{"key":"B157","doi-asserted-by":"publisher","first-page":"e55897","DOI":"10.1016\/S2213-2600(20)30448-3","article-title":"Adjunctive host-directed therapies for pulmonary tuberculosis: A prospective, open-label, phase 2, randomised controlled trial","volume":"9","author":"Wallis","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B158","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.brainresbull.2016.02.011","article-title":"Resveratrol provides neuroprotection by inhibiting phosphodiesterases and regulating the cAMP\/AMPK\/SIRT1 pathway after stroke in rats","volume":"121","author":"Wan","year":"2016","journal-title":"Brain Res. Bull."},{"key":"B159","doi-asserted-by":"publisher","first-page":"484.e17","DOI":"10.1016\/j.urology.2012.02.027","article-title":"A prospective, controlled phase II study of neoadjuvant exisulind therapy before radical prostatectomy: Effect on apoptosis","volume":"80","author":"Weight","year":"2012","journal-title":"Urology"},{"key":"B160","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/jps.2600611003","article-title":"Effects of therapeutic agents on cyclic AMP metabolism in vitro","volume":"61","author":"Weinryb","year":"1972","journal-title":"J. Pharm. Sci."},{"key":"B161","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1021\/jm50001a001","article-title":"A new generation of phosphodiesterase inhibitors: Multiple molecular forms of phosphodiesterase and the potential for drug selectivity","volume":"28","author":"Weishaar","year":"1985","journal-title":"J. Med. Chem."},{"key":"B162","doi-asserted-by":"publisher","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B163","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1002\/jbmr.4115","article-title":"Regular supplementation with resveratrol improves bone mineral density in postmenopausal women: A randomized, placebo-controlled trial","volume":"35","author":"Wong","year":"2020","journal-title":"J. Bone Min. Res."},{"key":"B164","unstructured":"Cardiovascular diseases (CVDs)2022"},{"key":"B165","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/archderm.107.1.47","article-title":"Defects and deficiency of adenyl cyclase in psoriatic skin","volume":"107","author":"Wright","year":"1973","journal-title":"Arch. Dermatol."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1095\/biolreprod64.6.1746","article-title":"Stage and cell-specific expression of calmodulin-dependent phosphodiesterases in mouse testis","volume":"64","author":"Yan","year":"2001","journal-title":"Biol. Reprod."},{"key":"B167","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1002\/cpbi.96","article-title":"Using ggtree to visualize data on tree-like structures","volume":"69","author":"Yu","year":"2020","journal-title":"Curr. Protoc. Bioinforma."},{"key":"B168","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/13543776.2020.1709444","article-title":"Phosphodiesterase 10 (PDE10) inhibitors: An updated patent review (2014-present)","volume":"30","author":"Zag\u00f3rska","year":"2020","journal-title":"Expert Opin. Ther. Pat."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1057083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T13:19:40Z","timestamp":1728479980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1057083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":170,"alternative-id":["10.3389\/fphar.2022.1057083"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1057083","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"article-number":"1057083"}}